Elevated CSF levels of matrix metalloproteinase‐12 as a potential marker for microhemorrhage risk in autosomal dominant Alzheimer disease
Nelly Joseph‐Mathurin, Katherine Gong, Gengsheng Chen, Parinaz Massoumzadeh, Jeremy F. Strain, Laura Ibáñez, Brian Andrew Gordon, Jorge J. Llibre‐Guerra et al.. Alzheimer s & Dementia, 2025-12-01
Topic: Amyloid, tau and blood-test diagnosis
Eight proteins were differently expressed in carriers with larger WMH volumes (Figure 1). The genes of seven proteins (e.g., neurofilament light-chain (NEFL), neurofilament heavy-chain (NEFH), matrix metalloproteinase 12 (MMP12), fibronectin-1 (FN1), periostin (POSTN)) were overly represented in vascular-related disorders such as subarachnoid hemorrhages, transient ischemic attack, or cerebrovascular diseases (Figure 2). CSF levels of NEFL, NEFH, MMP12, fibronectin1, and periostin differed as a function of CMH severity. Especially, NEFL and MMP12 were higher in carriers with severe CMH compared to those with none or mild CMH (Figure 3A). MMP12 levels were particularly high in participants having severe increase in microhemorrhages (Figure 3B). Carriers with high levels of MMP12 may more likely develop new microhemorrhages. Our findings confirm the contribution of neurofilament light chain in disease processes and suggest a role for matrix metalloproteinase 12 in the development of microhemorrhages and especially severe case in ADAD. FUNDING: K01AG080123, RF1-AG044546, UF1AG032438.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Joseph‐Mathurin, N., Gong, K., Chen, G., Massoumzadeh, P., Strain, J. F., Ibáñez, L., et al. (2025). Elevated CSF levels of matrix metalloproteinase‐12 as a potential marker for microhemorrhage risk in autosomal dominant Alzheimer disease. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_107566
Vancouver
Joseph‐Mathurin N, Gong K, Chen G, Massoumzadeh P, Strain JF, Ibáñez L, et al. Elevated CSF levels of matrix metalloproteinase‐12 as a potential marker for microhemorrhage risk in autosomal dominant Alzheimer disease. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_107566. PMID: 41518635.
BibTeX
@article{josephmathurin2025-41518635,
author = {Joseph‐Mathurin, Nelly and Gong, Katherine and Chen, Gengsheng and Massoumzadeh, Parinaz and Strain, Jeremy F. and Ibáñez, Laura and Gordon, Brian Andrew and Llibre‐Guerra, Jorge J. and others},
title = {{Elevated CSF levels of matrix metalloproteinase‐12 as a potential marker for microhemorrhage risk in autosomal dominant Alzheimer disease}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz70856_107566},
pmid = {41518635},
url = {https://doi.org/10.1002/alz70856_107566}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Eight proteins were differently expressed in carriers with larger WMH volumes (Figure 1).
- The genes of seven proteins (e.g., neurofilament light-chain (NEFL), neurofilament heavy-chain (NEFH), matrix metalloproteinase 12 (MMP12), fibronectin-1 (FN1), periostin (POSTN)) were overly represented in vascular-related disorders such as subarachnoid hemorrhages, transient ischemic attack, or cerebrovascular diseases (Figure 2).
- CSF levels of NEFL, NEFH, MMP12, fibronectin1, and periostin differed as a function of CMH severity.
- Especially, NEFL and MMP12 were higher in carriers with severe CMH compared to those with none or mild CMH (Figure 3A).
- MMP12 levels were particularly high in participants having severe increase in microhemorrhages (Figure 3B).
Why it matters
In carriers of autosomal dominant Alzheimer's disease, higher CSF levels of matrix metalloproteinase-12 were found in those with severe cerebral microhemorrhages, suggesting MMP12 may be a marker for microhemorrhage risk. This is a biomarker association study and does not test a treatment or cure.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Evidence strengthLow
How this study scored 31/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 30 of the 96 points we could judge it on, which is 31 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 0 / 7 | Cited 0 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 0 / 6 | Cited 0.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Dominantly Inherited Alzheimer Network holds only 3 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 2 / 3 | Washington University in St. Louis: institution h-index 1,962 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41518635) |
| Free to read | 2 / 2 | Free to read |
| Points | 30 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 30 of the 96 points we could judge it on is 31 out of 100. |
| Total | 31 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1002/alz70856_107566
- PubMed: 41518635
- Original source →
- Free full text: Alzheimer s & Dementia →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Genetics
Also tagged “cerebrospinal”
821 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 821 tagged studies.